Business Context and Reporting Period
This Form 8-K is filed by Cerecor Inc. (not Avalo Therapeutics, Inc.) on May 9, 2017. The filing serves to announce the company's financial results for the first quarter and three months ended March 31, 2017. The specific financial data is contained in a press release furnished as Exhibit 99.1, which is incorporated by reference but not deemed "filed" under Section 18 of the Exchange Act.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the attached press release (Exhibit 99.1), which is not included in the source text.
Material Changes
The filing does not provide specific details regarding material changes versus the prior comparable period. It only confirms the issuance of results for the first quarter of 2017.
Guidance, Outlook, and Risks
The filing text does not include management commentary, forward-looking guidance, specific risk factors, or contingencies. It strictly functions as a notification of the press release availability.
Important Facts for Investors to Verify
- Verify the actual financial figures (revenue, net loss, cash position) by reviewing the press release attached as Exhibit 99.1, as they are absent from the 8-K body text.
- Note the discrepancy between the requested company name (Avalo Therapeutics, Inc.) and the actual registrant (Cerecor Inc.).
- Confirm the date of the press release referenced in the exhibit index, as the text contains conflicting dates (May 9, 2017, in Item 2.02 vs. March 14, 2017, in the Exhibit Index).
- Understand that the financial information in this 8-K is "furnished" and not "filed," meaning it is not subject to the liabilities of Section 18 of the Exchange Act.